Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT06280885 Not yet recruiting - Cancer Clinical Trials

A Flexible Individualized ExeRcise Programme for Cancer Patients During ChEmotherapy

FIERCE
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The primary aim of this study is to measure the feasibility of delivering a co-designed exercise programme for patients with cancer receiving chemotherapy treatment.

NCT ID: NCT06275854 Not yet recruiting - Breast Cancer Clinical Trials

YASU Research Registry: For Young Adults With Cancer

Start date: May 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational research registry is to learn about health, wellbeing, and needs of survivors of young adult cancer (diagnosed between the ages of 18 and 39). The main question[s] it aims to understand are: - What are the levels of depression, anxiety, social support, and financial distress - Determine effectiveness of YASU programming by measuring changes over time With this registry, the investigators also plan to identify survivors who may be eligible for participation in future research studies pertaining to young adult cancer. Participants will be asked to complete electronic surveys every 6 to 12 months during participation in the registry.

NCT ID: NCT06274437 Not yet recruiting - Cancer Clinical Trials

A Study of BND-35 in Participants With Advanced Solid Tumors

Start date: April 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, dose escalation and dose optimization study designed to evaluate safety, tolerability and preliminary anti-tumor activity of BND-35 administered alone and in combination with nivolumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy. The study will be comprised of two parts - a dose escalation phase (Part 1) and a dose optimization (Part 2). Part 1 is comprised of three sub-parts: BND-35 administered alone (Sub-Part 1A), BND-35 administered in combination with nivolumab (Sub-Part 1B), and BND-35 administered in combination with cetuximab (Sub-Part 1C). Part 2 is composed of two sub-parts: a dose optimization part where up to two doses of BND-35 per indication are administered in combination with nivolumab or with cetuximab.

NCT ID: NCT06267014 Not yet recruiting - Breast Cancer Clinical Trials

Use of a Virtual Reality Cognitive Stimulation Programme for Breast Cancer Patients Wishing to Restart or Maintain a Professional Activity

Cog-RV
Start date: March 2024
Phase: N/A
Study type: Interventional

The study concerns patients who have been treated for breast cancer, have cognitive problems and are planning to return to work or are currently working and wish to begin cognitive rehabilitation. Patients will follow the Virtual Reality program developed for the study, during the cognitive rehabilitation usually proposed in the establishment, at the rate of a weekly session of 10-15 minute for 6 weeks.

NCT ID: NCT06259136 Not yet recruiting - Cancer Clinical Trials

Palliative Care Yields Cancer Wellbeing Support

Pal-Cycles
Start date: March 2024
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the effectiveness of a programme for transitional palliative cancer care (Pal-Cycles) in seven countries (the Netherlands, Germany, United Kingdom, Hungary, Poland, Romania and Portugal) and its consequent effects on the number of readmissions into hospital. The main hypothesis for the study is: that fewer people in the intervention arm of the study will require hospital re admission than those having usual care. Participants will be asked to fill in questionnaires regarding their quality of care and quality of life.

NCT ID: NCT06253338 Not yet recruiting - Cancer Clinical Trials

Optimization of Radiation Protection Through Genomic Analyses

ORtogether
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The long-term goal is to define "signatures" in the form of genomic changes through sequence analyses of genomic DNA using modern Next Generation Sequencing (NGS) methods, which 1. determine the radiation exposure of humans. 2. provide information about the exposure (dose). 3. determine the radiation quality. 4. predict the repair capacity and radiation resistance of an individual.

NCT ID: NCT06251648 Not yet recruiting - Cancer Clinical Trials

Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)

Start date: February 1, 2024
Phase:
Study type: Observational

Although lenalidomide (LEN) have proved effective in treating many cancers, few patients receiving LEN may experience rare but life-threatening adverse events such as Acute Lymphoblastic Leukaemia (ALL). Today, data about ALL are scarce. The objective was to investigate reports of ALL adverse events related to LEN in patients with cancer using the World Health Organization (WHO) pharmacovigilance database.

NCT ID: NCT06248216 Not yet recruiting - Cancer Clinical Trials

Virtual Reality Therapy for Cancer-Treatment Associated Symptoms

Start date: July 2024
Phase: N/A
Study type: Interventional

We propose an innovative approach to symptom management in cancer patients following cancer treatments, utilizing a Multimodal Integrative Therapy (MIT) delivered via Virtual Reality (VR) program, authorized by the US Food and Drug Administration for in-home use. Our primary goal is to generate pilot data on the effects of MIT-VR program on pain, fatigue, sleep, depression, and anxiety in participants suffering from chronic cancer symptoms following cancer treatments.

NCT ID: NCT06237816 Not yet recruiting - Cancer Clinical Trials

CTNow: A Clinical Trials Education Program for Rural Cancer Patients and Oncology Providers

Start date: June 2024
Phase: N/A
Study type: Interventional

The overall goal of the project is to pilot test CTNow, a multilevel intervention designed to facilitate access and referrals to cancer clinical trials in rural areas through patient and provider education and teleconference resources.

NCT ID: NCT06235671 Not yet recruiting - Cancer Clinical Trials

Effects of Chiropractic on Chronic Cancer-related Fatigue

CAN
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The primary aims of the proposed trial are centered around examining the feasibility of conducting a prospective, chiropractic intervention study on a population of cancer survivors living in and around Atlanta, Georgia. This includes evaluating various implementation outcomes including recruitment, adherence, tolerability, retention, acceptability, and data fidelity. The results of this trial will inform the design of a future randomized controlled trial (RCT) that has an increased focus on the efficacy/effectiveness of chiropractic care on chronic cancer-related fatigue (CCRF) and other cancer-related sequelae in cancer survivors.